Department of Clinical Pharmacology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Antimicrob Agents Chemother. 2011 Jul;55(7):3067-74. doi: 10.1128/AAC.01433-10. Epub 2011 May 2.
Although the influence of protein binding (PB) on antibacterial activity has been reported for many antibiotics and over many years, there is currently no standardization for pharmacodynamic models that account for the impact of protein binding of antimicrobial agents in vitro. This might explain the somewhat contradictory results obtained from different studies. Simple in vitro models which compare the MIC obtained in protein-free standard medium versus a protein-rich medium are prone to methodological pitfalls and may lead to flawed conclusions. Within in vitro test systems, a range of test conditions, including source of protein, concentration of the tested antibiotic, temperature, pH, electrolytes, and supplements may influence the impact of protein binding. As new antibiotics with a high degree of protein binding are in clinical development, attention and action directed toward the optimization and standardization of testing the impact of protein binding on the activity of antibiotics in vitro become even more urgent. In addition, the quantitative relationship between the effects of protein binding in vitro and in vivo needs to be established, since the physiological conditions differ. General recommendations for testing the impact of protein binding in vitro are suggested.
虽然多年来已有许多抗生素的相关研究报告指出蛋白结合(protein binding,PB)会影响抗生素的抗菌活性,但目前仍未有标准化的药效模型可用来评估抗菌药物在体外的蛋白结合对其产生的影响。这或许可以解释不同研究中得到的结果有些相互矛盾。简单的体外模型,将无蛋白标准培养基中获得的 MIC 值与富含蛋白的培养基中获得的 MIC 值进行比较,容易产生方法学上的缺陷,并可能导致错误的结论。在体外试验系统中,一系列试验条件,包括蛋白来源、测试抗生素的浓度、温度、pH 值、电解质和补充剂等,可能会影响蛋白结合的影响。随着具有高度蛋白结合的新型抗生素正在临床开发中,关注并采取行动来优化和标准化体外试验中蛋白结合对抗生素活性的影响变得更加紧迫。此外,由于生理条件不同,需要建立体外和体内蛋白结合作用之间的定量关系。建议提出了一些关于体外试验中蛋白结合影响的测试的一般建议。